• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Peptide firm Diatide to go public

Article

Peptide imaging agent developer Diatide of Londonderry, NH, planson issuing an initial public offering in the next several weeksthat will raise $25 million to fund ongoing product development.The firm will price its stock at $10 to $12 a share,

Peptide imaging agent developer Diatide of Londonderry, NH, plans

on issuing an initial public offering in the next several weeks

that will raise $25 million to fund ongoing product development.

The firm will price its stock at $10 to $12 a share, according

to president Richard Dean. Diatide's lead product is a technetium-99m-labeled

agent for detection of deep vein thrombosis.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.